Sign In
Buy APHB
$5.23
+0 (+0%)
At Close: Aug 17, 2022
AmpliPhi Biosciences and C3J Therapeutics Agree to Merge
08:00am, Friday, 04'th Jan 2019
SAN DIEGO & LOS ANGELES--(BUSINESS WIRE)--AmpliPhi Biosciences Corporation (“AmpliPhi”) (NYSE American: APHB), a clinical-stage biotechnology company focused on the development of precisely target
AmpliPhi Biosciences to Hold 2018 First Quarter and Business Update Conference Call on May 15
06:50am, Tuesday, 08'th May 2018
SAN DIEGO--(BUSINESS WIRE)--AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections u
AmpliPhi Biosciences Announces Positive Interim Results for Single-Patient Expanded Access Program Utilizing AB-SA01 and AB-PA01
04:05pm, Wednesday, 03'rd Jan 2018
SAN DIEGO--(BUSINESS WIRE)--AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resis
AmpliPhi Biosciences to Hold 2017 Third Quarter and Business Update Conference Call on November 14
04:05pm, Wednesday, 08'th Nov 2017
SAN DIEGO--(BUSINESS WIRE)--AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections u
AmpliPhi Biosciences to Hold 2017 Second Quarter and Business Update Conference Call on August 14
06:50am, Monday, 07'th Aug 2017
SAN DIEGO--(BUSINESS WIRE)--AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of therapies to treat drug-resistant infections using bacteriophage-based technology,
AmpliPhi Biosciences to Hold Business Update Conference Call on May 15
06:50am, Thursday, 11'th May 2017
SAN DIEGO--(BUSINESS WIRE)--AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, ann
CORRECTING and REPLACING AmpliPhi Biosciences Reports Favorable Final Results From Phase 1 Trial of AB-SA01
01:24pm, Monday, 05'th Dec 2016
SAN DIEGO--(BUSINESS WIRE)--Reissuing release to correct ticker symbol for searching purposes. The corrected release reads: AMPLIPHI BIOSCIENCES REPORTS FAVORABLE FINAL RESULTS FROM PHASE 1 TRIAL OF A
SAN DIEGO--(BUSINESS WIRE)--AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today
AmpliPhi Biosciences to Host Conference Call and Webcast Discussion of First Quarter 2016 Financial Results on May 13, 2016
08:45am, Tuesday, 10'th May 2016
SAN DIEGO--(BUSINESS WIRE)--AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today
AmpliPhi Biosciences to Host Full-Year 2015 Financial Results Conference Call and Webcast on March 30, 2016
08:45am, Tuesday, 29'th Mar 2016
SAN DIEGO--(BUSINESS WIRE)--AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announc
AmpliPhi BioSciences to Host Shareholder Update Conference Call
07:11pm, Tuesday, 30'th Dec 2014
RICHMOND, Va. & LJUBLJANA, Slovenia & SYDNEY--(BUSINESS WIRE)--AmpliPhi BioSciences Corporation (OTCQB:APHB) (“AmpliPhi”), the leader in the discovery and development of bacteriophage based therap
